Saturday 17 October 2026
Export PYPD’s income statement to Excel — free account
PolyPid Ltd.
PYPD Healthcare Biotechnology
In the quarter to June 2026, EPS grew 55.1%, free cash flow fell 65.0% and total debt fell 88.4%, each against the same quarter a year earlier.
4.75
0.15
−3.06%
Follow PYPD
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(390.53%) | (366.29%) | (758.61%) | (243.59%) | |
| (147.37%) | (143.79%) | (186.78%) | (119.05%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(200.32%) | (271.57%) | (325.96%) | (456.80%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
0.00 | (4.36) | 0.00 | (3.40) | |
Free Cash Flow |
— | (71.37) | — | (76.90) | |
Capital Expenditures |
— | (0.32) | — | (0.51) | |
| Other line items | |||||
Cash ROIC |
0.00% | (284.48%) | 0.00% | (632.49%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
— | 0.00% | — | 0.00% | |
Operating CF/Net income |
0.00 | 2.08 | 0.00 | 2.42 | |
Depreciation/Fixed assets |
0.00 | 0.91 | 0.00 | 1.00 | |
Capex/Depreciation |
— | (0.07) | — | (0.11) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
0.00 | (4.34) | 0.00 | (3.37) | |
Capex per Share |
0.00 | (0.02) | 0.00 | (0.02) | |
Capex to Sales |
— | 0.00 | — | 0.00 |
Columns are period end dates